Association of overweight/obesity and overweight/obesity-related metabolic dysfunction-associated steatotic liver disease in young adults with coronary artery calcification later in life

被引:2
|
作者
Wang, Jia-Jie [1 ]
Zheng, Zhichao [1 ]
Zhang, Ying [1 ]
机构
[1] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Cardiol, 106 Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China
来源
DIABETES OBESITY & METABOLISM | 2024年 / 26卷 / 09期
关键词
CAC; MASLD; obesity; overweight; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; RISK DEVELOPMENT; UNITED-STATES; WEIGHT-LOSS; OBESITY; PREVALENCE; NUTRITION; ADOLESCENTS; MANAGEMENT;
D O I
10.1111/dom.15733
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimThe association of overweight/obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) in young adulthood with subclinical atherosclerosis [coronary artery calcification (CAC) and abdominal aortic calcification (AAC)] by middle age is unknown.MethodIn total, 2274 participants aged 28-39 years from the coronary artery risk development in young adults study at year 10 (1995-1996) who were re-examined 15 years later were included. CAC and AAC were measured at year 25 using computed tomography. We examined the utility of three young adult phenotypes (lean group; overweight/obese group; overweight/obese MASLD group) at year 10 in predicting CAC or AAC by middle age. Modified Poisson regression was used to estimate the association between groups and CAC, and AAC. Independent determinates of CAC and AAC were determined with linear regression models.ResultsCompared with individuals categorized as lean in young adulthood, the relative risk for CAC by middle age was 1.09 (95% confidence interval: 0.93-1.28) for those with overweight/obesity and 1.32 (95% confidence interval: 1.08-1.61) for those with overweight/obesity-related MASLD. For AAC, no difference was observed between these three groups. Group, systolic blood pressure and group x systolic blood pressure interaction were all the independent determinates for CAC.ConclusionIn this study, young adults with overweight/obesity-related MASLD have a higher risk of developing CAC by middle age. These abnormalities are only partially explained by traditional cardiovascular risk factors, and overweight/obesity-related MASLD has an independent impact on CAC. Our study provides evidence for identifying young adults at higher risk of developing subclinical atherosclerosis.
引用
收藏
页码:3860 / 3867
页数:8
相关论文
共 50 条
  • [21] Influence of metabolic dysfunction-associated steatotic liver disease and of its genetics on kidney function in childhood obesity
    Di Sessa, Anna
    Rimoli, Antonietta
    Tirelli, Paola
    Rivetti, Giulio
    del Giudice, Emanuele Miraglia
    Guarino, Stefano
    Marzuillo, Pierluigi
    PEDIATRIC NEPHROLOGY, 2024, 39 (01) : S93 - S94
  • [22] Diverse Functions of Macrophages in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Inflammation and Metabolism
    Jang, Jun Hee
    Sung, Jin Hyun
    Huh, Jin Young
    IMMUNE NETWORK, 2025, 25 (01)
  • [23] Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults
    Jennifer N Cooper
    Linda Fried
    Ping Tepper
    Emma Barinas-Mitchell
    Molly B Conroy
    Rhobert W Evans
    Maria Mori Brooks
    Genevieve A Woodard
    Kim Sutton-Tyrrell
    Hypertension Research, 2013, 36 : 895 - 901
  • [24] Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults
    Cooper, Jennifer N.
    Fried, Linda
    Tepper, Ping
    Barinas-Mitchell, Emma
    Conroy, Molly B.
    Evans, Rhobert W.
    Brooks, Maria Mori
    Woodard, Genevieve A.
    Sutton-Tyrrell, Kim
    HYPERTENSION RESEARCH, 2013, 36 (10) : 895 - 901
  • [25] Association between life's essential 8 and metabolic dysfunction-associated steatotic liver disease among US adults
    Wang, Zheng
    Huang, Bohan
    Ding, Yixuan
    Cao, Feng
    Li, Fei
    Li, Prof Fei
    ARCHIVES OF PUBLIC HEALTH, 2024, 82 (01)
  • [26] Predicting hepatic steatosis degree in metabolic dysfunction-associated steatotic liver disease using obesity and lipid-related indices
    Forouzesh, Paniz
    Kheirouri, Sorayya
    Alizadeh, Mohammad
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [27] Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease
    Gries, Jacob J.
    Lazarus, Jeffrey, V
    Brennan, Paul N.
    Siddiqui, Mohammad S.
    Targher, Giovanni
    Lang, Chim C.
    Virani, Salim S.
    Lavie, Carl J.
    Isaacs, Scott
    Arab, Juan Pablo
    Cusi, Kenneth
    Krittanawong, Chayakrit
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (01): : 82 - 94
  • [28] Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer
    Moon, Sang Yi
    Son, Minkook
    Cho, Jung-Hwan
    Kim, Hye In
    Han, Ji Min
    Bae, Ji Cheol
    Suh, Sunghwan
    THYROID, 2025, 35 (01) : 79 - 86
  • [29] Bariatric surgery and cardiovascular outcomes in patients with obesity, metabolic dysfunction-associated steatotic liver disease, and coronary artery disease: a population-based matched cohort study
    Krishnan, Arunkumar
    Sims, Omar T.
    Teran, Daniel
    Woreta, Tinsay A.
    Hutson, William R.
    Alqahtani, Saleh A.
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2025,
  • [30] EFFECT OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS ON METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND WITH OVERWEIGHT OR OBESITY: A TARGET TRIAL EMULATION STUDY
    Nguyen, Mindie
    Mao, Xianhua
    Zhang, Xinrong
    Lai, Rongtao
    Yuen, Man-Fung
    Cheung, Ramsey
    Cheung, Ka-Shing
    Seto, Wai-Kay
    HEPATOLOGY, 2024, 80 : S885 - S886